Detalhe da pesquisa
1.
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
Lancet Oncol
; 25(2): 175-183, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38218192
2.
FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease.
Radiology
; 306(2): e220749, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36594838
3.
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).
Eur J Nucl Med Mol Imaging
; 50(9): 2830-2845, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246997
4.
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model.
Eur J Nucl Med Mol Imaging
; 49(3): 871-880, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34537893
5.
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
Lancet Oncol
; 22(8): 1115-1125, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34246328
6.
Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity.
Eur J Nucl Med Mol Imaging
; 49(1): 54-63, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34448031
7.
68Ga-FAPI-PET/CT in patients with various gynecological malignancies.
Eur J Nucl Med Mol Imaging
; 48(12): 4089-4100, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34050777
8.
Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients.
Eur J Nucl Med Mol Imaging
; 48(13): 4377-4385, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34137945
9.
The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study.
Eur J Nucl Med Mol Imaging
; 48(12): 4067-4076, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34031719
10.
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial).
Eur J Nucl Med Mol Imaging
; 48(1): 113-122, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32383093
11.
Internal Radiation Therapy.
Recent Results Cancer Res
; 216: 881-902, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32594411
12.
Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT.
Eur J Nucl Med Mol Imaging
; 46(1): 139-147, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30151743
13.
Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing "the lead" into PSMA-targeted alpha therapy?
Eur J Nucl Med Mol Imaging
; 46(5): 1081-1091, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30603987
14.
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).
Eur J Nucl Med Mol Imaging
; 46(12): 2536-2544, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31440799
15.
DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay.
Mutagenesis
; 34(3): 239-244, 2019 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31107537
16.
Liver metastasis of a neuroendocrine tumor demonstrates intense uptake in PSMA-PET-but not its lymph-node metastasis and primary-tumor.
Eur J Nucl Med Mol Imaging
; 50(7): 2226-2227, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36780004
17.
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617.
Eur J Nucl Med Mol Imaging
; 45(1): 31-37, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28891033
18.
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.
Eur J Nucl Med Mol Imaging
; 45(12): 2045-2054, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29980832
19.
Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study.
Eur J Nucl Med Mol Imaging
; 45(3): 340-347, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29038888
20.
Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.
Eur J Nucl Med Mol Imaging
; 44(6): 950-959, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28280855